Diane C. Haldane

• Led enterprise real-world data (RWD) strategy initiatives supporting drug development, evidence generation, market access, and commercialization across Lilly's portfolio.
• Drove identification, evaluation, acquisition, onboarding, and operationalization of fit-for-purpose RWD assets, including claims, EHR/EMR, registry, clinicogenomic, laboratory, and emerging data sources.
• Served as subject matter expert for Lilly's licensed RWD ecosystem, maintaining strategic oversight of enterprise data assets and advising stakeholders on data selection and utilization.
• Partnered with Medical Affairs, HEOR, Global Patient Safety, Lilly Value and Access, Tech@Lilly, Statistics, and business leaders to develop data-driven solutions supporting critical scientific and business decisions.
• Led evaluation and implementation of innovative RWD capabilities, including AI ChatBot, integrated evidence generation, and advanced analytics platforms.
• Established and maintained strategic relationships with external data vendors, research organizations, and industry consortia to expand data capabilities and maximize value from enterprise data investments.
• Developed governance frameworks, standards, and best practices for data access, privacy, compliance, quality assessment, and lifecycle management.
• Oversaw maintenance of enterprise RWD inventories, metadata, knowledge management resources, and data enablement processes supporting global user communities.
• Provided enterprise-wide consultation, training, and education on RWD sources, observational research methodologies, coding systems, and fit-for-purpose data selection.
• Led cross-functional initiatives focused on data strategy, operational excellence, vendor management, and continuous improvement of RWD capabilities.
• Drove adoption of new data assets and analytic capabilities through stakeholder engagement, communication, change management, and data literacy initiatives.

• Led statistical analyst team in support of global real-world evidence research and evidence-generation initiatives.
• Provided programming and analytic support for retrospective and prospective studies across multiple therapeutic areas.
• Designed and implemented scalable data and analytics infrastructure supporting claims, EHR, survey, and registry-based research.
• Developed enterprise epidemiology reporting frameworks that accelerated study planning and evidence generation.
• Designed and led deployment of Lilly's External Healthcare Information (EHI) data mart, integrating multiple healthcare data sources.
• Architected and implemented enterprise analytics environments utilizing Netezza, SAS Grid, and AWS technologies.
• Led strategic initiatives focused on RWD sourcing, privacy, access and use, knowledge management, CRM integration, and analytics enablement.
• Served as trusted advisor and consultant to scientists, statisticians, epidemiologists, and HEOR researchers on the use of healthcare databases and observational research methods.
• Aligned regional and global standards, governance processes, and quality expectations across RWD and clinical analytics environments.
• Served as Lilly co-lead supporting FDA Sentinel Initiative and contributed to industry collaborations, including OMOP and eHI drug safety programs.

• Managed a U.S.-based Phase IV statistical analyst organization comprising 23 direct reports.
• Directed staffing, performance management, mentoring, and resource allocation to support organizational and project objectives.
• Oversaw project execution and drove continuous process improvement initiatives to enhance team efficiency and delivery quality.
• Led post-marketing analytics supporting clinical and commercial research initiatives.
• Provided statistical programming and analysis support for Phase III-IV clinical studies and commercial analytics projects.

• Supported healthcare operations and medical management organizations through advanced claims analysis and reporting.
• Identified claims processing issues to improve accuracy and operational efficiency across healthcare data workflows.
• Detected fraud opportunities through data analysis, contributing to stronger claims oversight and risk mitigation.
• Delivered reporting and analytical insights to support medical management decision-making and operational performance.
• Drove operational improvements through evaluation of claims data and identification of process gaps.
• Generated over $6 million in annual savings by uncovering claims issues, fraud opportunities, and areas for operational enhancement.

• Performed statistical programming and analysis for Phase III-IV clinical trials across multiple therapeutic areas.

• Directed a team of analysts supporting managed care reporting, quality improvement initiatives, utilization management, provider profiling, disease management, and HEDIS reporting.
• Led analytical support for managed care operations to strengthen reporting accuracy and inform business and clinical priorities.
• Conducted healthcare utilization, cost, and outcomes analyses to support payer operations and performance evaluation.
• Delivered analysis to inform provider quality initiatives and enable data-driven strategic decision-making.
• Supported utilization management efforts through reporting and analytical insight across health services functions.
• Contributed to quality improvement and disease management programs through comprehensive health services information and analysis.

Health and Human Development

Psychology, Graduation with Distinction